Zura Bio (NASDAQ:ZURA) Rating Reiterated by HC Wainwright

Zura Bio (NASDAQ:ZURA)‘s stock had its “neutral” rating reaffirmed by stock analysts at HC Wainwright in a research report issued to clients and investors on Monday, Benzinga reports. They currently have a $5.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 1.63% from the company’s current price.

A number of other equities analysts have also recently weighed in on ZURA. Piper Sandler reaffirmed an “overweight” rating and issued a $26.00 price target on shares of Zura Bio in a report on Thursday, September 19th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zura Bio in a research note on Friday, October 18th.

Zura Bio Price Performance

Shares of ZURA stock opened at $4.92 on Monday. The business has a 50-day simple moving average of $3.95 and a 200-day simple moving average of $3.98. Zura Bio has a 52-week low of $2.00 and a 52-week high of $6.35.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). As a group, sell-side analysts expect that Zura Bio will post -0.47 EPS for the current year.

Insiders Place Their Bets

In other Zura Bio news, Director Someit Sidhu sold 51,728 shares of the business’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $3.87, for a total transaction of $200,187.36. Following the completion of the sale, the director now directly owns 2,085,418 shares in the company, valued at approximately $8,070,567.66. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 15.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Zura Bio

A number of large investors have recently made changes to their positions in ZURA. Point72 Asset Management L.P. purchased a new stake in shares of Zura Bio in the second quarter valued at approximately $8,446,000. Great Point Partners LLC grew its position in shares of Zura Bio by 68.3% in the second quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock valued at $16,248,000 after purchasing an additional 1,884,501 shares in the last quarter. Armistice Capital LLC grew its position in shares of Zura Bio by 53.2% in the second quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock valued at $8,834,000 after purchasing an additional 876,000 shares in the last quarter. Affinity Asset Advisors LLC purchased a new stake in shares of Zura Bio in the first quarter valued at approximately $1,157,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Zura Bio in the third quarter valued at approximately $62,000. 61.14% of the stock is currently owned by hedge funds and other institutional investors.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.